VanEck Biotech ETF
BBH
102 hedge funds and large institutions have $121M invested in VanEck Biotech ETF in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 13 closing their positions.
13% more call options, than puts
Call options by funds: $239K | Put options by funds: $211K
1.54% less ownership
Funds ownership: 29.97% → 28.43% (-1.5%)
6% less funds holding
Funds holding: 108 → 102 (-6)
8% less capital invested
Capital invested by funds: $132M → $121M (-$10.2M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
37% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGFC
Peapack-Gladstone Financial Corp
Bedminster,
New Jersey
|
+$4.36M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.79M |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$1.59M |
| 5 |
LJAC
L.J. Altfest & Co
New York
|
+$846K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$4.75M |
| 2 |
CCA
Conservest Capital Advisors
Wynnewood,
Pennsylvania
|
-$3.49M |
| 3 |
Morgan Stanley
New York
|
-$1.88M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.64M |
| 5 |
LPL Financial
San Diego,
California
|
-$1.51M |
BBH Hedge Fund Activity: Q3 2022 in Review
102 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2022, worth a combined $121M — down 7.8% from $132M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BBH and 10 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 19 added.
The largest buyer was Peapack-Gladstone Financial Corp, opening a new position worth an estimated $4.36M. The largest seller was Bank of America, cutting an estimated $4.75M.
- 102 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2022, down from 108 in Q2 2022.
- Funds reported $121M of VanEck Biotech ETF stock for Q3 2022, down 7.8% quarter-over-quarter.
- 10 funds opened new VanEck Biotech ETF positions in Q3 2022 and 13 closed out, a net change of -3 holders.
- The largest VanEck Biotech ETF buyer in Q3 2022 was Peapack-Gladstone Financial Corp, an estimated $4.36M added.
- The largest VanEck Biotech ETF seller in Q3 2022 was Bank of America, an estimated $4.75M sold.
Based on aggregated 13F filings for Q3 2022.